Abiopharma

🔍 Samuel George A. III (Executive)

Company: Lineage Cell Therapeutics, Inc. (LCTX)

Report Date: 2026-02-11

Detailed Transactions and Holdings:

• Acquired 6,075 shares of Common Shares (Direct)
  Date: 2026-02-11 | Code: M | equity_swap_involved: false | shares_owned_after: 33,565.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
• Sold 2,502 shares of Common Shares at $1.8 per share (Direct)
  Date: 2026-02-11 | Code: F | equity_swap_involved: false | shares_owned_after: 31,063.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 6,075 shares of Restricted Stock Units (Derivative)
  Date: 2026-02-11 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4

Footnotes:

• F1: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
• F2: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
• F3: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,075 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction
• F4: The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.